zervimesine

Asset

Antagonizes sigma-2 receptors to prevent toxic protein oligomers from binding to neurons.

Stage: Phase 3
Modality: Small molecule
Target: Proteostasis; 1
Indication: 0
Trials: 1
Developer

Indications

1

Dementia with Lewy bodies
Phase 3, longevity.technology, 9 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets2
Competitors5
Aging relevance1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.